Jacobi Capital Management LLC Sells 352 Shares of iShares Biotechnology ETF $IBB

Jacobi Capital Management LLC lessened its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 13.0% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,346 shares of the financial services provider’s stock after selling 352 shares during the period. Jacobi Capital Management LLC’s holdings in iShares Biotechnology ETF were worth $300,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Ramirez Asset Management Inc. acquired a new position in iShares Biotechnology ETF in the first quarter valued at about $26,000. Financial Gravity Asset Management Inc. acquired a new position in iShares Biotechnology ETF in the first quarter valued at about $30,000. Woodside Wealth Management LLC acquired a new position in iShares Biotechnology ETF in the first quarter valued at about $31,000. CX Institutional acquired a new position in iShares Biotechnology ETF in the first quarter valued at about $32,000. Finally, Garde Capital Inc. acquired a new position in iShares Biotechnology ETF in the first quarter valued at about $36,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

NASDAQ:IBB opened at $140.98 on Friday. iShares Biotechnology ETF has a 1-year low of $107.43 and a 1-year high of $150.57. The business’s 50-day moving average price is $135.67 and its two-hundred day moving average price is $129.10.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.